Pharmaceutical Chemistry: Towards Full-Cycle Production round table discussion was held as part of the business program at ChemTech Ural 2026. Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, was the keynote speaker at the event.
Scientists from the Federal Research Center of Biotechnology of the Russian Academy of Sciences (RAS), in collaboration with Medsintez Plant, have developed a cell line that produces an analog of dulaglutide, a drug used to treat patients with type 2 diabetes. In the context of import substitution, creating a domestic bioanalog of this critically needed medication is of paramount importance. At the request of their industrial partner, the scientists utilized a previously engineered apoptosis-resistant cell line to develop an approach that accelerates the generating of stable producers and increases the yield of the target protein. The results of this study have been published in the Pharmaceuticals journal.
+7 (34370) 2-50-61
+7 (34370) 2-54-95
Torgovaya 15, Novouralsk, Sverdlovsk region, Russia, 624130
Для использования сайта дайте согласие на обработку файлов cookie и ваших персональных данных, в т.ч. с помощью сервиса «Яндекс Метрика», в соответствии с Политикой по обработке персональных данных путем нажатия на кнопку «Ок»